Journal article

The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft

Matthew J Rees, Peter Mollee, Jun Yen Ng, Alex Murton, Jose Filipe Gonsalves, Ashish Panigrahi, Hayley Beer, Joanna Loh, Philip Nguyen, Sam Hunt, Hayden Jina, Rebecca Wayte, Gaurav Sutrave, Jocelyn Tan, Chathuri Abeyakoon, Ashlyn Chee, Bradley Augustson, Akash Kalro, Cindy Lee, Shivam Agrawal Show all

Bone Marrow Transplantation | SPRINGERNATURE | Published : 2021


G-CSF only mobilisation has been shown to enhance immune reconstitution early post-transplant, but its impact on survival remains uncertain. We undertook a retrospective review of 12 transplant centres to examine overall survival (OS) and time to next treatment (TTNT) following melphalan autograft according to mobilisation method (G-CSF only vs. G-CSF and cyclophosphamide [CY]) in myeloma patients uniformly treated with bortezomib, cyclophosphamide and dexamethasone induction. Six centres had a policy to use G-CSF alone and six to use G-CSF + CY. Patients failing G-CSF only mobilisation were excluded. 601 patients were included: 328: G-CSF + CY, 273: G-CSF only. Mobilisation arms were compar..

View full abstract

University of Melbourne Researchers